Study directory

Mental health studies with practical context.

Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.

Back to overview
3186studies shown
Showing 2,876-2,900 of 3,186
CompletedNCT01244490

Efficacy and Safety of Extended-release Guanfacine Hydrochloride in Children and Adolescents Aged 6-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)

This study exists to compare options and see whether this type of care offers something meaningfully different. For people living with ADHD, that matters because care needs to work in daily life, not just in theory.

ADHDOtherFrom 6 Years to 17 Years
Countries
Austria, Canada, France, Germany, Ireland, Italy, Poland, Romania, Spain, Sweden, Ukraine, United Kingdom, United States
Sponsor
Shire
Condition
ADHD
CompletedNCT03292952

KP415 Classroom Study in Children (6-12 Years of Age) With ADHD

This study exists to compare options and see whether a medication treatment offers something meaningfully different. Researchers are trying to understand whether a medication treatment can improve attention, thinking, or day-to-day functioning.

ADHDOtherFrom 6 Years to 12 Years
Countries
United States
Sponsor
Zevra Therapeutics
Condition
ADHD
CompletedNCT02255513

A Trial Evaluating the Efficacy and Safety of HLD200 in Children With ADHD

This study exists to understand whether a medication treatment is both safe enough and useful enough to take further. Researchers are trying to understand how people respond to a medication treatment in practice and what may need to be adjusted.

ADHDOtherFrom 6 Years to 12 Years
Countries
United States
Sponsor
Ironshore Pharmaceuticals and Development, Inc
Condition
ADHD
CompletedNCT00202605

Safety and Efficacy of SPD465 in Adults With ADHD

This study exists to compare options and see whether this type of care offers something meaningfully different. Researchers are trying to understand what this type of care could change in day-to-day care and decision-making.

ADHDOtherFrom 18 Years to 55 Years
Countries
United States
Sponsor
Shire
Condition
ADHD
CompletedNCT00764868

Vyvanse Adolescent Open-Label Safety and Efficacy Extension Study

This study exists to understand how a medication treatment holds up over time after the earliest research stage. Researchers are trying to understand how people respond to a medication treatment in practice and what may need to be adjusted.

ADHDOtherFrom 13 Years to 17 Years
Countries
United States
Sponsor
Shire
Condition
ADHD
CompletedNCT00367835

SPD503 (Guanfacine Hydrochloride) in ADHD Plus Oppositional Symptoms

This study exists to understand whether this type of care is both safe enough and useful enough to take further. For people living with ADHD, that matters because care needs to work in daily life, not just in theory.

ADHDOtherFrom 6 Years to 12 Years
Countries
United States
Sponsor
Shire
Condition
ADHD
CompletedNCT00734578

Efficacy and Safety of SPD503 in Combination With Psychostimulants

This study exists to understand whether this type of care is both safe enough and useful enough to take further. Researchers are trying to understand how people respond to this type of care in practice and what may need to be adjusted.

ADHDOtherFrom 6 Years to 17 Years
Countries
United States
Sponsor
Shire
Condition
ADHD
CompletedNCT00500149

A Classroom Study to Assess the Time of Onset of Vyvanse (Lisdexamfetamine Dimesylate) in Pediatric Subjects Aged 6-12 With Attention Deficit/Hyperactivity Disorder (ADHD)

This study exists to compare options and see whether this type of care offers something meaningfully different. Researchers are trying to understand whether this type of care can improve attention, thinking, or day-to-day functioning.

ADHDOtherFrom 6 Years to 12 Years
Countries
United States
Sponsor
Shire
Condition
ADHD
CompletedNCT01081145

Maintenance of Efficacy of Extended-Release Guanfacine HCl in Children and Adolescents With Attention-deficit/Hyperactivity Disorder (ADHD)

This study exists to understand how this type of care holds up over time after the earliest research stage. Researchers are trying to understand whether this type of care can improve attention, thinking, or day-to-day functioning.

ADHDOtherFrom 6 Years to 17 Years
Countries
Belgium, Canada, France, Germany, Italy, Netherlands, Spain, Sweden, United Kingdom, United States
Sponsor
Shire
Condition
ADHD
CompletedNCT01106430

Comparison of Lisdexamfetamine Dimesylate With Atomoxetine HCl in Attention-Deficit/Hyperactivity Disorder (ADHD) Subjects With an Inadequate Response to Methylphenidate

This study exists to better understand the safety of a therapy or guided support program and how manageable it feels in practice. Researchers are trying to understand how people respond to a therapy or guided support program in practice and what may need to be adjusted.

ADHDOtherFrom 6 Years to 17 Years
Countries
Belgium, Canada, Germany, Hungary, Italy, Poland, Spain, Sweden, United Kingdom, United States
Sponsor
Shire
Condition
ADHD
CompletedNCT00697515

Safety and Efficacy Workplace Environment Study of Lisdexamfetamine Dimesylate (LDX) in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)

This study exists to compare options and see whether the medication Lisdexamfetamine offers something meaningfully different. Researchers are trying to understand what the medication Lisdexamfetamine could change in day-to-day care and decision-making.

ADHDOtherFrom 18 Years to 55 Years
Countries
United States
Sponsor
Shire
Condition
ADHD
CompletedNCT00784654

Double-blind, Placebo-controlled, Randomised Withdrawal, Extension, Safety and Efficacy Study of LDX in Children and Adolescents Aged 6-17

This study exists to understand how the medication LDX holds up over time after the earliest research stage. For people living with ADHD, that matters because care needs to work in daily life, not just in theory.

ADHDOtherFrom 6 Years to 17 Years
Countries
Belgium, France, Germany, Hungary, Italy, Poland, Sweden, United Kingdom, United States
Sponsor
Shire
Condition
ADHD